Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Trusted and respected experts involved in every trial

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Using the FDA compliant manual over-read approach, the QT interval is measured by our cardiologists on screen using electronic callipers(MUSE CV® Interval Editor, GE Marquette Medical Systems) with sufficient magnification allowing the measurement precision equal to the storage frequency of 500 MHz, i.e. ±1 ms. Whilst the details of the analysis can be discussed and agreed with our clients at the study design stage, as a matter of routine, in each ECG the QT interval is measured in all 12 leads. The median QT interval of all measurable beats from the 12 leads is then taken as valid for that particular ECG.

The measured and verified QT intervals are corrected for heart rate using conventional population-derived formulae (e.g. Fridericia) or an individually derived formula. The QT/QTc interval data are then subjected to a statistical analysis in accordance with the current regulatory guidelines which also includes input and interpretation of the results from one of our experienced cardiological scientists.

In line with the current regulatory requirements and at least every six months, all cardiologists working for Richmond Pharmacology undertake intra- and inter-reader variability tests under blinded conditions to ensure that our measurements are accurate and reproducible. Furthermore, systematic in–process QC checks are performed by a senior cardiologist during a specific study analysis. All QC checks and any corrective actions are reconciled and fully documented.

When you conduct your study with Richmond Pharmacology, you benefit from the expertise of globally recognised key opinion leaders

Get in touch today

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event